Controversial FDA vaccine chief Dr. Vinay Prasad exits agency again
Read Original Source
In this undated photo provided by the U.S. Food and Drug Administration, Vinay Prasad smiles for a portrait. (U.S. FDA via AP) The Food and Drug Administration seal is seen at the Hubert Humphrey Building Auditorium in Washington, April 22, 2025. (AP Photo/Jose Luis Magana, File) WASHINGTON (AP) — The Food and Drug Administration’s embattled vaccine chief, Dr.
AI Summary
Main Idea: Dr. Vinay Prasad is leaving the FDA again after a series of disputes over vaccine and drug reviews drew heavy criticism.
Key Points:
- FDA Commissioner Marty Makary told staff that Prasad will depart at the end of April and return to his job at UC San Francisco.
- Prasad had already been forced out once this year before coming back with support from Health Secretary Robert F. Kennedy Jr. and Makary.
- His latest trouble grew after the FDA first refused to review Moderna’s mRNA flu vaccine, then reversed course and agreed to review it with more study.
- The FDA also clashed publicly with a drug company over an experimental Huntington’s disease gene therapy, including a demand for a new trial that would use a sham surgery.
Impact on the People
Negative Impact
Prasad’s exit may add more FDA shake-ups, which can delay drug and vaccine reviews and create more uncertainty for patients, companies, and investors.
Positive Impact
The change could ease conflict at the FDA and lead to steadier decisions on medicines and vaccines.
How did each entity affect people?
Rate how each entity in this article affected the American people.
- Primary:Dr. Vinay Prasadperson
- Major:Modernacompany
Candidate Entities9 candidates · 5 weighted vote min · 70% decision
- Dr. Vinay PrasadpersonPrimaryEvaluated
Central figure in the story; the article is about his departure from the Food and Drug Administration and.
Include 0 (0%)Ignore 0 (0%)5 to threshold - ModernacompanyMajorEvaluated
Named drugmaker central to the article’s dispute with the Food and Drug Administration over a flu vaccine review.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Marty MakarypersonMajorAI selected
Food and Drug Administration commissioner who announced Prasad’s exit and is directly involved in the agency’s actions.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Robert F. Kennedy Jr.personMajorAI selected
Health Secretary whose backing helped restore Prasad earlier and who is part of the article’s account of agency.
Include 0 (0%)Ignore 0 (0%)5 to threshold - UniQurecompanyMajorAI selected
Named biotech company at the center of the article’s latest regulatory conflict with the Food and Drug Administration.
Include 0 (0%)Ignore 0 (0%)5 to threshold - President Donald TrumppersonContextCandidate
Mentioned as the president whose conservative allies and administration politics are part of the context for Prasad’s departure.
Include 0 (0%)Ignore 0 (0%)5 to threshold - University of California, San Franciscoeducational / research institutionContextCandidate
Prasad’s academic employer to which he is said to be returning.
Include 0 (0%)Ignore 0 (0%)5 to threshold
Comments 0
Comments here are the same thread shown when this article appears in The Pulse.
No comments on this article yet.
Sign in to comment